RiiQ™ increasingly being used as a primary endpoint

A new Phase IIb clinical trial by Enanta Pharmaceuticals has commenced.

The RiiQ™ is being used to evaluate the effectiveness of EDP-938, a potent N-protein inhibitor for RSV compared with a placebo for 5 days.

The time to RSV lower respiratory tract disease symptoms resolution, as evaluated by the Respiratory Infection Intensity and Impact Questionnaire (RiiQ™) over 33 days is the trial’s primary endpoint.
See here for more details.